Showing contents from:

Implementing Health Catalyst Products & Services

Extended Real-World Data: The Life Science Industry’s Number One Asset

The life science industry has historically relied on sanitized clinical trials and commoditized data sources (largely claims) to inform its drug development process—an under-substantiated approach that didn’t reflect how a new drug would affect broader patient populations. In an effort to gain more accurate insight into the patient experience and bring drugs to market more efficiently and safely, the industry is now expanding into extended real-world data (RWD).

To access the needed breadth and depth of patient-centric data, life science companies must partner with a healthcare transformation company that has three key qualities:

  1. A broad and deep data asset.
  2. Extensive provider partnerships.
  3. An outcomes-improvement engine to support the next generation of drug development.

The Key to Healthcare Mergers and Acquisitions Success: Don’t Rip and Replace Your IT (Executive Report)

Healthcare mergers and acquisitions can involve a lot of EMRs and other IT systems. Sometimes leaders feel like they have to rip and replace these systems to fully integrate organizations. However, this is not the answer, according to Dale Sanders. This report, based upon his July 2017 webinar, outlines the importance of a data-first strategy and introduces the Health Catalyst® Data Operating System (DOS™) platform. DOS can play a critical role in facilitating IT strategy for the growing healthcare M&A landscape.